Research programme: antibody therapeutics - Enumeral Biomedical

Drug Profile

Research programme: antibody therapeutics - Enumeral Biomedical

Alternative Names: 244C8; 388D4; Allosteric anti-PD-1 antibodies - Enumeral; ENUM 244C8; ENUM005; ENUM008; ENUM009

Latest Information Update: 21 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enumeral Biomedical Holdings; University of Texas M. D. Anderson Cancer Center
  • Developer Enumeral Biomedical Holdings
  • Class Antibodies
  • Mechanism of Action CD223 antigen inhibitors; Checkpoint kinase inhibitors; HAVCR2 protein inhibitors; OX40 ligand inhibitors; Programmed cell death-1 receptor antagonists; TIGIT protein inhibitors; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer
  • Research Inflammation

Most Recent Events

  • 10 Nov 2016 Antibody therapeutics from Enumeral Biomedical are available for licensing as of 10 Nov 2016.
  • 15 Jul 2016 Pharmacodynamics and safety data from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 06 Jun 2016 Pieris Pharmaceuticals in-licenses anti-PD-1 antibody program from Enumeral Biomedical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top